Homoharringtonine binds to and increases myosin‐9 in myeloid leukaemia

Background and PurposeHomoharringtonine (HHT) is a natural alkaloid isolated from various Cephalotaxus species. HHT has been used to treat acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocyte leukaemia and myelodysplastic syndromes. Although HHT inhibits protein synthesis and promotes apoptosis of leukaemia cells in preclinical studies, its molecular target proteins remain unknown. The aim of this study was to identify target proteins of HHT.Experimental ApproachWe have synthesized a biotinylated affinity column and used it to identify targets of HHT and confirmed the results by MS and Western blots. We also examined the effects of HHT on the target protein and determined roles of the target protein in anti‐leukaemia activities of HHT through Western blots, flow cytometry and retrovirus transfection.Key ResultsMyosin‐9, a member of the myosin super‐family, was identified as a direct interactor of HHT. Furthermore, HHT up‐regulated the expression level of myosin‐9 in both AML and CML cell lines in a time‐dependent manner. Thus, HHT‐induced apoptosis of leukaemia cells begins in 6 h and continues to increase for 24 h. There is a positive correlation between up‐regulated myosin‐9 expression level and increased percentage of apoptotic cells mediated by HHT. Overexpression of myosin‐9 could increase the sensitivity of the leukaemia cells to the cytotoxicity of HHT and arrest cells in S and G2/M phases.Conclusions and ImplicationsOur results indicated that myosin‐9 was the target protein of HHT and played an important role in the HHT‐induced apoptosis of leukaemia cells.